CD274 and non-small cell lung carcinoma: Several clinical trials using anti-PD-1 and anti-PD-L1 monoclonal antibodies, including nivolumab (BMS-936558)70, 71, pembrolizumab (MK-3475)72, and atezolizumab (MPDL3280A)73 have shown promising clinical activity in advanced NSCLC.